Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) fell 4.7% on Thursday . The company traded as low as $9.36 and last traded at $9.43. Approximately 486,023 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 3,063,639 shares. The stock had previously closed at $9.89.
Capricor Therapeutics News Summary
Here are the key news stories impacting Capricor Therapeutics this week:
- Positive Sentiment: Analyst upgrade and FDA review extension provide support. Piper Sandler upgraded Capricor, while reports highlighted that the FDA extended its review of deramiocel. The extension keeps the regulatory process active and may give the company additional time to address outstanding questions regarding the treatment for Duchenne muscular dystrophy complications. Capricor Therapeutics Shares Rise After Piper Sandler Upgrade
- Neutral Sentiment: Investors have until September 28, 2026, to seek lead-plaintiff status. Numerous law firms reiterated that shareholders who purchased CAPR securities generally between December 17, 2025, and July 26, 2026, may seek appointment as lead plaintiff in the pending federal class action. These announcements are procedural and do not establish wrongdoing or guarantee investor recovery. CAPR Investor Deadline Class Action Notice
- Negative Sentiment: Multiple securities lawsuits allege Capricor misled investors about deramiocel and the HOPE-3 trial. The complaints reportedly focus on alleged deviations from prespecified blinding, study-protocol and statistical-analysis procedures, as well as alleged misrepresentations about the path to FDA approval. The litigation follows FDA briefing documents associated with an alleged decline of approximately $15.08 per share and could create legal costs, reputational damage and additional regulatory uncertainty. CAPR Securities Class Action Deadline Alert
Wall Street Analyst Weigh In
A number of research analysts have recently commented on CAPR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Oppenheimer raised shares of Capricor Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, August 25th. LADENBURG THALM/SH SH downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, July 30th. B. Riley Financial cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 price objective for the company. in a research report on Monday, July 27th. Finally, JonesTrading downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $29.15.
Capricor Therapeutics Stock Down 5.7%
The company has a 50 day moving average of $13.29 and a two-hundred day moving average of $24.00. The firm has a market cap of $542.21 million, a P/E ratio of -3.81 and a beta of 0.72.
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Research analysts expect that Capricor Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.
Insider Activity
In related news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the sale, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. The trade was a 68.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 25,000 shares of company stock valued at $759,158. Insiders own 9.20% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in CAPR. Montanova Capital LLC lifted its position in shares of Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after acquiring an additional 274,184 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after acquiring an additional 355,161 shares during the last quarter. Suvretta Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $51,533,000. Tang Capital Management LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter valued at $49,062,000. Finally, California State Teachers Retirement System lifted its holdings in shares of Capricor Therapeutics by 2,261.8% during the second quarter. California State Teachers Retirement System now owns 1,528,478 shares of the biotechnology company’s stock valued at $36,806,000 after purchasing an additional 1,463,762 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
Featured Stories
- Five stocks we like better than Capricor Therapeutics
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
- One of Trump’s Favorite Stocks Just Reported Blowout Earnings
- Amazon’s Robot Push Raises a Bigger Question About Its Next Margin Lever
- Palo Alto Networks Is Expensive—But Its Growth Is Accelerating
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
